The effectiveness of 1 mg/day Colchicine in the treatment of patients with ocular involvement in Behcet's Disease
Phase 4
- Conditions
- Ocular involvement in Behcet's disease.behcet's disease
- Registration Number
- IRCT138808062641N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
diagnosed Behcet's disease according to Iran's diagnostic tree criteria, signing the informed consent, not being pregnant or breast feeding, no history of malignancy, age more than16, posterior uveitis or retinitis in latest ophtalmological visit
Exclusion criteria: blood dyscrasia, pregnancy, low compliance
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie colchicine's efficacy in treating ocular Behcet's disease?
How does 1 mg/day colchicine compare to standard-of-care therapies for uveitis in Behcet's patients?
Are there specific biomarkers that correlate with colchicine response in ocular Behcet's disease?
What are the potential adverse events associated with long-term colchicine use in Behcet's disease patients?
What combination therapies involving colchicine show promise in managing Behcet's ocular manifestations?